Newest
-
LTG is about to be listed on BiFinance, the world's most fully licensed exchange, aiming to usher in a new chapter for the Bitcoin Depin ecosystem through the Lightning Network.
-
China Southern Power Grid's First Overseas Distribution Network Loss Reduction Pilot Project—the South Cairo, Egypt Project—has Successfully Passed Acceptance
-
AIX Incubator Secures U.S. SEC Filing Approval and MSB License, Advancing Its Global Compliance Strategy
-
RWA2035 Global Digital Economy Strategy Summit to Debut in Boao on January 4, 2026
Bridge Biotherapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2025-01-03
IDOPRESS
SEONGNAM,South Korea and BOSTON,Dec. 30,2024 -- Bridge Biotherapeutics (KQ288330),a clinical-stage biotech company based inSouth Koreadeveloping novel drugs for fibrosis and cancer,today announced thatJames Jungkue Lee,Founder and CEO of Bridge Biotherapeutics,will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday,January 16,2025.
Location: Georgian Room (Mezzanine Level) at The Westin St. Francis
Date: Thursday,2025
Time: 9:45-10:25 a.m. PST
During the conference,BridgeBiotherapeutics will also meet with potential partners and investors as the Company is looking for Business Development opportunities for further development of BBT-877,a novel drug candidate for idiopathic pulmonary fibrosis (IPF). Top-line results from the Phase 2 study of BBT-877 are expected in April 2025.
To arrange a meeting with the Bridge Biotherapeutics team,send a meeting request here.
About Bridge Biotherapeutics,Inc.
Bridge Biotherapeutics Inc.,based in the Republic of Korea and the U.S.,is a publicly traded,clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics,focusing on therapeutic areas with high unmet needs,including fibrotic diseases and cancers. The company is developing BBT-877,a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF),and BBT-207,a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with EGFR C797S mutations. Learn more at https://www.bridgebiorx.com/en/.